About this trial
Diabetes mellitus type 2 is associated with significant morbidity and mortality; and identifying new treatments for diabetes complications to be used alone or in combination with other therapies is a high priority. Hyperglycemia triggers proinflammatory pathways leading to damage in the kidneys, eyes and blood vessels; thus targeting proinflammatory lipid mediators called leukotrienes may represent a promising therapy for diabetes complications. This clinical trial seeks to investigate whether montelukast, a leukotriene antagonist, improves kidney, eye and vascular function in adult participants with type 2 diabetes and kidney disease.
Eligibility criteria
Qualifiers
Diabetes type 2
Urine albumin to creatinine ratio 30-5000 mg/g
CKD stage 2-3 (eGFR 30-89 ml/min/1.73m2)
Blood pressure < 140/90 mmHg prior to randomization
Disqualifiers
Type 1 diabetes
Uncontrolled hypertension
Hemoglobin A1C >10%
Pregnancy or planning to become pregnant or currently breastfeeding
Trial design
Treatments tested in this trial
- Montelukast
- Placebo